29Oct, 2026 CereVasc Receives FDA IDE Approval to Evaluate the eShunt® System in Patients with Alzheimer’s DiseaseCarlos Bonilla2026-10-28T21:33:47+00:00October 29th, 2026|Press Release|Read More
15Sep, 2026 CereVasc, Inc. Appoints Tony Kingsley as President and Chief Executive OfficerCarlos Bonilla2026-09-15T11:59:43+00:00September 15th, 2026|Press Release|Read More
30Jul, 2026 CereVasc Opens New Massachusetts Facility in Preparation for eShunt® System CommercializationCarlos Bonilla2026-07-30T02:45:22+00:00July 30th, 2026|Press Release|Read More
23Jun, 2026 CereVasc, Inc. Completes Enrollment in STRIDE Pivotal Trial of the eShunt® SystemCarlos Bonilla2026-06-22T20:44:28+00:00June 23rd, 2026|Press Release|Read More
04Jun, 2026 CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure HydrocephalusDaniel Nunez2026-06-04T09:55:23+00:00June 4th, 2026|Press Release|Read More
04Mar, 2026 First-in-Human Use of CereVasc® eShunt® System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical OutcomesCarlos Bonilla2026-06-02T13:12:28+00:00March 4th, 2026|Press Release|Read More
24Feb, 2026 CereVasc, Inc. Announces Publication of a Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPHCarlos Bonilla2026-10-29T21:07:19+00:00February 24th, 2026|Press Release|Read More
21Jan, 2026 CereVasc Completes Enrollment of ETCHES Study of the eShunt® System for the Treatment of Communicating HydrocephalusAnthony Sherwood2026-01-29T21:40:11+00:00January 21st, 2026|Press Release|Read More
30Jul, 2025 CereVasc, Inc. Announces 100th Patient Treated with the eShunt® SystemAnthony Sherwood2026-01-29T21:41:12+00:00July 30th, 2025|Press Release|Read More
18Jun, 2025 CereVasc Receives Health Canada Investigational Testing Authorization for STRIDE Clinical Trial of the eShunt® SystemAnthony Sherwood2026-01-29T21:42:02+00:00June 18th, 2025|Press Release|Read More
